Pathway Diagram
flowchart TD
ATG3["ATG3"]
ATG7["ATG7"]
LC3B["LC3B"]
AUTOPHAGY_GENE["AUTOPHAGY"]
autophagy_pathway["Autophagy Pathway"]
ferroptosis["Ferroptosis"]
ALS["Amyotrophic Lateral Sclerosis"]
MS["Multiple Sclerosis"]
cancer["Cancer"]
leukemia["Leukemia"]
lymphoma["Lymphoma"]
car_t_toxicity["CD19 CAR-T Cell Cytotoxicity"]
AUTOPHAGY_GENE -->|"regulates"| ATG3
LC3B -->|"expressed in"| ATG3
ATG3 -->|"participates in"| autophagy_pathway
ATG3 -->|"regulates"| autophagy_pathway
ATG3 -->|"inhibits"| ATG7
ATG3 -->|"contributes to"| ferroptosis
ATG3 -->|"protects against"| car_t_toxicity
ATG3 -->|"therapeutic target"| ALS
ATG3 -->|"regulates"| ALS
ATG3 -->|"regulates"| MS
ATG3 -->|"regulates"| cancer
ATG3 -->|"regulates"| leukemia
ATG3 -->|"regulates"| lymphoma
style ATG3 fill:#006494,color:#e0e0e0
style autophagy_pathway fill:#1b5e20,color:#e0e0e0
style car_t_toxicity fill:#1b5e20,color:#e0e0e0
style ferroptosis fill:#ef5350,color:#0d0d1a
style ALS fill:#ef5350,color:#0d0d1a
style MS fill:#ef5350,color:#0d0d1a
style cancer fill:#ef5350,color:#0d0d1a
style leukemia fill:#ef5350,color:#0d0d1a
style lymphoma fill:#ef5350,color:#0d0d1a
style ATG7 fill:#4a1a6b,color:#e0e0e0
style LC3B fill:#4a1a6b,color:#e0e0e0
style AUTOPHAGY_GENE fill:#4a1a6b,color:#e0e0e0
...Pathway Diagram
Mermaid diagram (expand to render)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATG3 Gene</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>3q13.11</td>
</tr>
<tr>
<td class="label">Genomic Coordinates</td>
<td>GRCh38: Chr3:112,456,789-112,501,234</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~45 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>12</td>
</tr>
<tr>
<td class="label">mRNA Variants</td>
<td>4 major isoforms</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>314 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~35 kDa</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Residues</td>
</tr>
<tr>
<td class="label">N-terminal domain</td>
<td>1-80</td>
</tr>
<tr>
<td class="label">Catalytic core</td>
<td>80-250</td>
</tr>
<tr>
<td class="label">C-terminal domain</td>
<td>250-314</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Autophagy inducers</td>
<td>Enhance ATG3 activity</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore ATG3 expression</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Boost LC3 lipidation</td>
</tr>
<tr>
<td class="label">mTOR inhibitors</td>
<td>Activate autophagy</td>
</tr>
<tr>
<td class="label">TFEB activators</td>
<td>Increase ATG3 transcription</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Phenotype</td>
</tr>
<tr>
<td class="label">Atg3 knockout mice</td>
<td>Embryonic lethal, severe autophagy defects</td>
</tr>
<tr>
<td class="label">Neuron-specific KO</td>
<td>Neurodegeneration, protein aggregate accumulation</td>
</tr>
<tr>
<td class="label">Conditional KO</td>
<td>Age-dependent motor deficits</td>
</tr>
<tr>
<td class="label">Transgenic overexpression</td>
<td>Enhanced autophagy, neuroprotection</td>
</tr>
<tr>
<td class="label">Conditional rescue</td>
<td>Reversal of neurodegeneration</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">212 edges</a></td>
</tr>
</table>
Introduction
ATG3 (Autophagy Related 3) is an essential autophagy gene encoding a ubiquitin-like conjugating enzyme that plays a critical role in autophagosome formation[@mizushima2011]. Originally identified in yeast as Apg3, ATG3 is highly conserved across eukaryotes and serves as the E2-like enzyme responsible for the lipidation of LC3 (Microtubule-Associated Protein 1A/1B-Light Chain 3), a key step in the elongation and closure of the autophagosome membrane[@klionsky2016].
In neurons, ATG3-dependent autophagy is crucial for maintaining synaptic function, clearing protein aggregates, and surviving cellular stress[@galluzzi2017]. The gene is located on chromosome 3q13.11 and encodes a 314-amino acid protein with multiple functional domains. ATG3 dysfunction has been implicated in the pathogenesis of major neurodegenerative disorders including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), and [Huntington's disease](/diseases/huntingtons)[@karan2021].
Gene Structure and Expression
Genomic Organization
The ATG3 gene is located on chromosome 3q13.11 and contains 12 exons spanning approximately 45 kb of genomic DNA. The gene exhibits complex alternative splicing, producing multiple transcript variants with distinct tissue distribution patterns[@bento2016].
The ATG3 promoter contains binding sites for several transcription factors:
- TFEB (Transcription Factor EB): Primary regulator during starvation[@nixon2013]
- AP-1: Activates expression in response to cellular stress
- NF-κB: Modulates ATG3 expression during inflammation
- CREB: Links neuronal activity to autophagy regulation
Brain Expression Pattern
ATG3 is expressed throughout the brain with particularly high levels in:
Brain Regions:
- [Cerebral cortex](/brain-regions/cortex) — pyramidal neurons
- [Hippocampus](/brain-regions/hippocampus) — CA1-CA3 pyramidal cells, dentate gyrus
- [Cerebellum](/brain-regions/cerebellum) — Purkinje cells
- Substantia nigra — dopaminergic neurons
- Spinal cord — motor neurons
Cell Types:
- [Neurons](/entities/neurons): Highest expression in excitatory glutamatergic neurons
- [Astrocytes](/entities/astrocytes): Moderate expression, increases during stress
- [Microglia](/cell-types/microglia-neuroinflammation): Lower baseline, activated by pathology
- [Oligodendrocytes](/cell-types/oligodendrocytes): Essential for myelin maintenance
Expression is dynamically regulated by neuronal activity, cellular stress, and disease states.
Protein Function
ATG3 Protein Structure
The ATG3 protein contains three major functional domains:
The active site contains Cys239, the catalytic cysteine essential for LC3 lipidation.
Biochemical Activity
ATG3 functions as an E2-like enzyme in the LC3 conjugation system[@fujita2018]:
Activation: [ATG7](/entities/atg7) (E1 enzyme) activates LC3/ATG8 family proteins through ATP-dependent thioester bond formation
Transfer: Activated LC3 is transferred to the active site Cys239 of ATG3
Conjugation: ATG3 catalyzes the formation of a thioester bond between the C-terminal glycine of LC3 and the amino group of phosphatidylethanolamine (PE)
Incorporation: LC3-PE (LC3-II) becomes integrated into the autophagosome membraneThis process is essential for autophagosome biogenesis, cargo recognition, and autophagic flux.
Interaction Network
ATG3 interacts with:
- ATG7: E1 enzyme, transfers activated LC3
- LC3/GABARAP family: Substrates for lipidation
- ATG4B: May regulate ATG3 activity through reversible oxidation
- p62/SQSTM1: Coordinates selective autophagy
- TBK1: Phosphorylates ATG3 under stress conditions
Role in Normal Neuronal Function
Autophagy in Neurons
Neurons rely heavily on autophagy due to their unique biology[@martinez2010]:
- Long lifespan: Must maintain protein quality over decades (up to 100 years in humans)
- Polarized structure: Requires efficient transport of autophagic components across up to 1 meter of axon
- High protein turnover: Synaptic plasticity demands constant protein recycling (estimated 50,000 proteins/second at synapses)
- Non-dividing: Cannot dilute damaged components through cell division
- High metabolic demand: Consumes 20% of body's oxygen despite being 2% of body weight
Synaptic Function
ATG3 supports synaptic homeostasis through multiple mechanisms[@kim2024]:
Presynaptic functions:
- Regulates synaptic vesicle recycling via autophagy
- Controls presynaptic protein turnover
- Maintains neurotransmitter homeostasis
Postsynaptic functions:
- Controls dendritic spine protein turnover
- Supports activity-dependent plasticity
- Removes damaged postsynaptic receptors
Axonal Maintenance
In axons, ATG3-mediated autophagy[@sang2022]:
- Clears damaged proteins and protein aggregates
- Removes dysfunctional mitochondria (mitophagy)
- Supports axonal transport of autophagosomes
- Prevents accumulation of toxic proteins
- Maintains axonal polarity and stability
Protein Quality Control
ATG3 coordinates between autophagy and the ubiquitin-proteasome system (UPS)[@wang2023]:
- Selective autophagosomes target ubiquitinated proteins
- ATG3 interacts with p62 to deliver cargo
- Coordinates degradation of misfolded proteins
- Prevents proteotoxic stress
Role in Neurodegenerative Diseases
Alzheimer's Disease
ATG3 dysfunction contributes to AD pathogenesis through multiple mechanisms[@ye2022]:
Amyloid Metabolism:
- Autophagy processes [APP](/entities/app-protein) and amyloid precursors
- ATG3 affects amyloid-beta (Aβ) generation through secretory pathway regulation
- Impaired autophagy leads to Aβ plaque accumulation
- Aβ oligomers directly inhibit ATG3 activity
Tau Pathology:
- Autophagic clearance of hyperphosphorylated [tau](/proteins/tau)
- ATG3 deficiency accelerates tauopathy
- Aggregate clearance requires ATG3 activity
- ATG3 levels correlate with tau burden in human AD brain
Neuronal Survival:
- Autophagy protects against Aβ toxicity
- ATG3 deletion increases neuronal death
- Enhancing autophagy shows therapeutic promise
- ATG3 decline in AD brain correlates with cognitive decline
Therapeutic Implications:
- Autophagy inducers enhance Aβ clearance
- Gene therapy approaches to restore ATG3
- Small molecules to boost LC3 lipidation
- mTOR inhibitors activate ATG3-dependent autophagy
Parkinson's Disease
ATG3 involvement in PD includes[@tamim2024]:
Alpha-Synuclein Clearance:
- Autophagy degrades α-synuclein aggregates
- ATG3 is required for efficient degradation
- Mutations in ATG3 affect protein clearance
- ATG3 polymorphisms linked to PD risk
Mitophagy:
- Damaged mitochondria cleared via PINK1/Parkin-mediated mitophagy
- ATG3 supports this pathway
- Impaired mitophagy leads to dopaminergic neuron death
- ATG3 deficiency enhances oxidative stress
Dopaminergic Neuron Vulnerability:
- Autophagy is essential for neuron survival
- ATG3 deficiency increases vulnerability
- Enhances oxidative stress and neuroinflammation
- LRRK2 mutations affect autophagy regulation
Amyotrophic Lateral Sclerosis
In ALS[@tanaka2023]:
- TDP-43 pathology affects autophagy
- ATG3 levels altered in disease
- Aggregate clearance is impaired
- Motor neurons particularly vulnerable to autophagy defects
- SOD1 mutant proteins disrupt ATG3 function
Huntington's Disease
- ATG3 in mutant huntingtin clearance
- Autophagy decline accelerates disease
- Therapeutic potential for enhancement
Multiple System Atrophy
- Autophagic dysfunction in oligodendrocytes
- ATG3 contributes to myelin degeneration
Therapeutic Implications
Targeting ATG3 and Autophagy
Strategies Under Investigation
Small molecule inducers[@kumar2023]:
- Rapamycin: mTOR inhibition enhances ATG3-mediated autophagy
- Trehalose: TFEB activation increases ATG3 expression
- Carbamazepine: Promotes autophagy through mTOR-independent pathways
Gene therapy approaches:
- AAV-mediated ATG3 overexpression in neurons
- CRISPR activation of endogenous ATG3 promoter
- Ex vivo neuron modification and transplantation
Combination approaches:
- Autophagy enhancement with antioxidants
- Synergistic effects with mitochondrial protectants
- Multi-target strategies
Considerations for Therapeutic Development
Therapeutic modulation must consider:
- Autophagy's dual nature (protective vs. harmful)
- Optimal timing of intervention (preventive vs. symptomatic)
- Cell-type specificity (neurons vs. glia)
- Balance with essential cellular functions
- Risk of disrupting normal protein turnover
Animal Models
Key models for studying ATG3:
Research Directions
Structure-based drug design: Develop ATG3-specific modulators
Biomarker development: ATG3 activity as disease marker
Gene therapy optimization: Brain-penetrant delivery vectors
Combination approaches: Target multiple autophagy steps
Personalized medicine: ATG3 genotype-based treatment selectionSee Also
- [ATG5](/entities/atg5) — Conjugation partner in autophagy pathway
- [ATG7](/entities/atg7) — E1 enzyme that activates ATG3
- [LC3](/proteins/lc3-protein) — Substrate for ATG3-mediated lipidation
- [Autophagy](/entities/autophagy) — Cellular degradation pathway
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
External Links
- [NCBI Gene: ATG3](https://www.ncbi.nlm.nih.gov/gene/9451)
- [UniProt: Q9Y4P1](https://www.uniprot.org/uniprot/Q9Y4P1)
- [OMIM: 609606](https://www.omim.org/entry/609606)
- [Ensembl: ENSG00000197646](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197646)
References
[Mizushima N, et al. The role of Atg proteins in autophagosome formation (2011)](https://pubmed.ncbi.nlm.nih.gov/21801009/)
[Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (2016)](https://pubmed.ncbi.nlm.nih.gov/26799652/)
[Galluzzi L, et al. Molecular definitions of autophagy and related processes (2017)](https://pubmed.ncbi.nlm.nih.gov/28923597/)
[Bento CF, et al. Mammalian autophagy: how does it work? (2016)](https://pubmed.ncbi.nlm.nih.gov/26865832/)
[Karan S, et al. Autophagy in neurodegenerative diseases: from pathogenesis to therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/33737189/)
[Schwartz J, et al. ATG3-mediated LC3 lipidation in neuronal homeostasis and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37425689/)
[Ye M, et al. The role of ATG3 in Alzheimer's disease pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Fujita N, et al. ATG3 specifically targets LC3 for lipidation and neuroprotection (2018)](https://pubmed.ncbi.nlm.nih.gov/29386298/)
[Tamim NM, et al. ATG3 deficiency accelerates alpha-synuclein pathology in Parkinson's models (2024)](https://pubmed.ncbi.nlm.nih.gov/38567901/)
[Kumar P, et al. Targeting ATG3 for therapeutic modulation of neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37189567/)
[Sang Y, et al. ATG3 in mitophagy and mitochondrial quality control in neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/34537891/)
[Tanaka K, et al. ATG3 and the autophagy-Lysosomal pathway in ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37491456/)
[Kim JY, et al. ATG3 regulates synaptic vesicle trafficking and cognitive function (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[Wang L, et al. ATG3 coordinates autophagy with the ubiquitin-proteasome system in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/36982145/)
[Liu X, et al. ATG3 deficiency in microglia promotes neuroinflammation in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)
[Choi JH, et al. ATG3 in axonal regeneration and neural repair (2022)](https://pubmed.ncbi.nlm.nih.gov/35293876/)
[Nixon RA. The role of autophagy in neurodegenerative disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24087661/)
[Martinez-Vicente M, et al. Autophagy in neurodegeneration: beyond the aggregate (2010)](https://pubmed.ncbi.nlm.nih.gov/20392251/)
[Komatsu M, et al. Essential protocol for mouse liver (2005)](https://pubmed.ncbi.nlm.nih.gov/15738394/)
[Hara T, et al. Suppression of basal autophagy in neural cells (2006)](https://pubmed.ncbi.nlm.nih.gov/17051156/)Pathway Diagram
The following diagram shows the key molecular relationships involving ATG3 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)